<DOC>
	<DOCNO>NCT02603432</DOCNO>
	<brief_summary>The main purpose study compare maintenance treatment avelumab plus best supportive care ( BSC ) BSC alone , determine avelumab effect survival patient locally advance metastatic urothelial cancer worsen follow completion first-line chemotherapy .</brief_summary>
	<brief_title>A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer ( JAVELIN Bladder 100 )</brief_title>
	<detailed_description />
	<criteria>Histologically confirm , unresectable locally advanced metastatic transitional cell carcinoma urothelium Stage IV disease start firstline chemotherapy Measurable disease ( per RECIST v1.1 ) prior start firstline chemotherapy Prior firstline chemotherapy must consist least 4 cycle 6 cycle gemcitabine + cisplatin and/or gemcitabine + carboplatin No evidence progressive disease follow completion firstline chemotherapy ( i.e. , ongoing CR , PR , SD per RECIST v1.1 guideline ) Prior adjuvant neoadjuvant systemic therapy within 12 month randomization Prior immunotherapy IL2 , IFNÎ± , antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , CTLA 4 antibody ( include ipilimumab ) , antibody drug specifically target Tcell costimulation immune checkpoint pathway Persisting toxicity relate prior therapy ( Grade &gt; 1 NCI CTCAE v4.0 ) ; however , alopecia , sensory neuropathy ( Grade 2 less ) , ( Grade 2 less ) adverse event constitute safety risk base investigator 's judgement acceptable . Patients know symptomatic central nervous system ( CNS ) metastases require steroid Diagnosis malignancy within 5 year prior randomization , except adequately treat basal cell squamous cell skin cancer , carcinoma situ breast cervix , low grade prostate cancer surveillance without plan treatment intervention , prostate cancer adequately treat prostatectomy radiotherapy currently evidence disease symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Urologic neoplasm</keyword>
	<keyword>urothelial carcinoma</keyword>
	<keyword>PD-L1</keyword>
	<keyword>program cell death protein</keyword>
	<keyword>maintenance treatment</keyword>
</DOC>